Outcome measures in systemic sclerosis: an update on instruments and current research.
about
The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trialInfliximab may be effective in the treatment of steroid-resistant eosinophilic fasciitis: report of three cases.Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design.Correlates and responsiveness to change of measures of skin and musculoskeletal disease in early diffuse systemic sclerosis.Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosisOld medications and new targeted therapies in systemic sclerosis.Improvement of Mouth Functional Disability in Systemic Sclerosis Patients over One Year in a Trial of Fat Transplantation versus Adipose-Derived Stromal Cells.The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisA standardized core set for systemic sclerosis clinical trials. First step in development of combined response indexSkin involvement in systemic sclerosis.Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis.Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials.Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials.Development of a provisional core set of response measures for clinical trials of systemic sclerosis.Biomarkers in systemic sclerosis.Evidence-based management of rapidly progressing systemic sclerosis.The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisHealth State Utilities and Disease Duration in Systemic Sclerosis: Is There an Association?Altered T-cell and regulatory cell repertoire in patients with diffuse cutaneous systemic sclerosis.Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.Identification of novel systemic sclerosis biomarkers employing aptamer proteomic analysis.Immunogenicity and safety of pneumococcal vaccination in patients with systemic sclerosis.Translation, cultural adaptation and validation into portuguese (Brazil) in Systemic Sclerosis Questionnaire (SySQ).Clinical utility of hypo- and hyperpigmentation of skin in diffuse cutaneous systemic sclerosis.Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials.The assessment of immune-regulatory effects of extracorporeal photopheresis in systemic sclerosis: a long-term follow-up study.
P2860
Q33724464-16A83F8E-FBCF-483E-8267-C988790D43B1Q34019290-15AD8EA0-DCA3-4E44-B294-C95825489056Q34027197-2794ECA0-73DE-422B-8860-DC9A3F2C8BC0Q35878701-22CF6211-663E-4397-8C8F-8DC12646CBC7Q35977294-9F2F4D3C-2F39-4C47-A247-6D2058C65EC2Q36154430-CCF91776-8AA9-498F-83B2-C8A85A4B8468Q36530443-50897EDC-8B98-4D10-9780-3118E133A0E3Q36758822-F9955B18-E135-459C-A4E2-275701853CC3Q36869412-D37E700A-C0A8-47CD-B87C-16E975F129E3Q37265837-8A996625-8548-4135-83E6-F1604768DB14Q37282448-34960F85-738F-497F-85E9-0778B5AD8BC1Q37301159-77D88241-151D-4413-877D-BEFAD4FC7EE4Q37324622-7874DCAB-DF3B-479C-9BFC-22F36BD10388Q37460792-58396D56-E7AA-4289-915D-ECDDAFE602EAQ37730018-D2AC8013-F635-4129-9734-CC03D631CFE6Q37763779-E61D4262-D2C7-4F97-9789-7CB7DB695CD7Q40002833-65793D7D-A6CD-4544-8519-1B678C40456EQ41651775-F5459F35-BCF8-4B77-8792-879CAE7D9CACQ45937863-2C2855E5-BE6E-4AFF-B649-39D5AB7E20DCQ46479042-A4A12FBC-ACD7-4C99-B36C-6EE623B10675Q47400242-969970F3-712C-4A17-A04C-0CC931B542A1Q47554836-13BF1D47-953B-4DC2-B0DB-E8894454C6FCQ47638065-8B381D43-EB29-4D16-8956-3F4391BF68C3Q47839424-B45D57E2-ED43-41AE-A6EF-4DCBCB62A96AQ50623134-9F90C76A-BD5D-4E62-8160-F7A8A48468A6Q52931497-1C2B5618-33CF-4CAB-AA09-548914A97120
P2860
Outcome measures in systemic sclerosis: an update on instruments and current research.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Outcome measures in systemic sclerosis: an update on instruments and current research.
@en
type
label
Outcome measures in systemic sclerosis: an update on instruments and current research.
@en
prefLabel
Outcome measures in systemic sclerosis: an update on instruments and current research.
@en
P2860
P1476
Outcome measures in systemic sclerosis: an update on instruments and current research.
@en
P2093
Dinesh Khanna
Peter A Merkel
P2860
P2888
P304
P356
10.1007/S11926-007-0010-5
P577
2007-05-01T00:00:00Z